

Sequent Scientific announces addition of new state-of-art Animal Health R&D Centre at Mumbai

Mumbai, February 3, 2020: SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health (Alivira) & Analytical Services, today announced the inauguration of a new state-of-the-art multifaceted and dedicated Animal Health R&D centre at Ambernath in Mumbai.

This unique centre with strong injectable focus has capabilities to develop products of 8 different dosage forms including injectable solutions & suspensions, tablets, oral solutions & suspensions, granules, powders and premixes. Equipped with the best Lab to Pilot infrastructure, a team of 20+ research professionals with over 100+ years of experience, the centre is working on several differentiated products to cater to Alivira's Global market needs. In addition to product development, the team has developed capabilities to handle complex radio-labelled ecotoxicity studies and In-vitro palatability, tissue residue, bio-equivalence studies across a spectrum of livestock and companion animals.

*Commenting on the development, **Manish Gupta, Managing Director of SeQuent Scientific Limited** said: "We are pleased to announce the addition of a new animal health R&D centre at Ambernath equipped with state-of-the-art global infrastructure and multifaceted capability. The facility brings under one roof one of the most comprehensive R & D capabilities in the animal health space and will help us to increase our footprint in the regulated market."*

He also added "We also filed for the first and World's largest livestock injectable developed at this location and plans are afoot to file for 3 more injectables in FY 21."

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its Vizag facility is India's first and only USFDA approved facility for veterinary APIs.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer
Tel: +91 22 4111 4717
tushar.m@sequent.in

Diwakar Pingle

Christensen Investor Relations
Tel : +91 22 4215 0210
sbubna@christensenir.com

Abhishek Singhal

Investor Relations Consultants
abhishek.s@sequent.in

Registered Office

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

R&D Centre at Mumbai

